Assessment of Brachial Plexus Dose and Associated Toxicity in Nasopharyngeal Carcinoma Radiotherapy

<ns3:p> Introduction Radiation plexopathy is known to depend on various parameters, and is rarely reported in head&amp;neck cancers. While literature suggests dose constraints of 60-66 Gy, our study aimed to evaluate late brachial plexopathy after primary chemoradiotherapy for locally advanced nasopharyngeal carcinoma with IMRT, and determine the maximum tolerated dose. Methods Between May 2015 and March 2020, a retrospective cohort of 50 patients with a history of previously irradiated nasopharyngeal cancer was identified. All patients underwent definitive treatment using IMRT at recommended curative doses. Clinical and treatment-related characteristics were collected, and all cases were reviewed for symptoms of radiation-induced brachial plexopathy. Verbal informed consent was obtained from all patients prior to their inclusion in the study. Results Of the 50 patients, 98% received concurrent chemoradiotherapy. The mean age at treatment was 44 years. All patients received a maximum dose of ≥ 60 Gy. The maximum dose to the BP (BPmax) was 82.64 Gy (mean: 72.8 Gy). The mean dose received by 0.03 cm <ns3:sup>3</ns3:sup> of the BP was 71.74 Gy. Among patients with nodal involvement, 86% received a maximum dose of ≥ 66 Gy. A correlation study with N-category showed a significant increase in BPmax dose with increasing nodal stage. The mean BPmax for patients with level III/IV lymph nodes (75.19 Gy) was higher than for those with level I/II involvement (69.19 Gy) (P = 0.0001). All patients had a minimum follow-up of two years, with a mean follow-up duration of 37.5 months. Five patients reported clinical symptoms of acute or late brachial plexopathy, but none had confirmation via MRI or electromyography. Conclusion In our study using IMRT for nasopharyngeal cancer patients and with a minimum follow-up of two years, it appears safe to deliver &gt; 66 Gy to the brachial plexus. However, longer follow-up is required. </ns3:p>

Authors

Institutions

Publication Details

Journal
F1000Research
Published
2025-10-28
DOI
https://doi.org/10.12688/f1000research.168313.1
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessment of Brachial Plexus Dose and Associated Toxicity in Nasopharyngeal Carcinoma Radiotherapy

Alia Mousli, Mohamed Soussi, Rim Abidi, Asma Ghorbel et al.
F1000Research
Head and Neck Cancer Studies
article

Assessment of Brachial Plexus Dose and Associated Toxicity in Nasopharyngeal Carcinoma Radiotherapy

Alia Mousli, Mohamed Soussi, Rim Abidi, Asma Ghorbel, Najla Attia, Chiraz Nasr, Zidi Asma, Marwa Besbes, Fathia Abidi, Khedija Ben Zid, Cyrine Mokrani, Sarra Saidi
article en

Abstract

<ns3:p> Introduction Radiation plexopathy is known to depend on various parameters, and is rarely reported in head&amp;neck cancers. While literature suggests dose constraints of 60-66 Gy, our study aimed to evaluate late brachial plexopathy after primary chemoradiotherapy for locally advanced nasopharyngeal carcinoma with IMRT, and determine the maximum tolerated dose. Methods Between May 2015 and March 2020, a retrospective cohort of 50 patients with a history of previously irradiated nasopharyngeal cancer was identified. All patients underwent definitive treatment using IMRT at recommended curative doses. Clinical and treatment-related characteristics were collected, and all cases were reviewed for symptoms of radiation-induced brachial plexopathy. Verbal informed consent was obtained from all patients prior to their inclusion in the study. Results Of the 50 patients, 98% received concurrent chemoradiotherapy. The mean age at treatment was 44 years. All patients received a maximum dose of ≥ 60 Gy. The maximum dose to the BP (BPmax) was 82.64 Gy (mean: 72.8 Gy). The mean dose received by 0.03 cm <ns3:sup>3</ns3:sup> of the BP was 71.74 Gy. Among patients with nodal involvement, 86% received a maximum dose of ≥ 66 Gy. A correlation study with N-category showed a significant increase in BPmax dose with increasing nodal stage. The mean BPmax for patients with level III/IV lymph nodes (75.19 Gy) was higher than for those with level I/II involvement (69.19 Gy) (P = 0.0001). All patients had a minimum follow-up of two years, with a mean follow-up duration of 37.5 months. Five patients reported clinical symptoms of acute or late brachial plexopathy, but none had confirmation via MRI or electromyography. Conclusion In our study using IMRT for nasopharyngeal cancer patients and with a minimum follow-up of two years, it appears safe to deliver &gt; 66 Gy to the brachial plexus. However, longer follow-up is required. </ns3:p>

F1000ResearchVol. 14
Institut Salah-Azaïz (TN)
Openalex Percentile: Top 59%
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.